Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?

J Inherit Metab Dis. 2015 Mar;38(2):371-2. doi: 10.1007/s10545-014-9775-7. Epub 2014 Oct 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acyl-CoA Dehydrogenase, Long-Chain / deficiency*
  • Acyl-CoA Dehydrogenase, Long-Chain / genetics
  • Bezafibrate / adverse effects
  • Bezafibrate / therapeutic use*
  • Carnitine O-Palmitoyltransferase / deficiency*
  • Carnitine O-Palmitoyltransferase / genetics
  • Congenital Bone Marrow Failure Syndromes
  • Fatty Acids / metabolism*
  • Heart Rate / drug effects
  • Humans
  • Lipid Metabolism, Inborn Errors / diagnosis
  • Lipid Metabolism, Inborn Errors / drug therapy*
  • Lipid Metabolism, Inborn Errors / enzymology
  • Lipid Metabolism, Inborn Errors / genetics
  • Lipid Metabolism, Inborn Errors / physiopathology
  • Lipolysis / drug effects*
  • Metabolism, Inborn Errors / diagnosis
  • Metabolism, Inborn Errors / drug therapy*
  • Metabolism, Inborn Errors / enzymology
  • Metabolism, Inborn Errors / genetics
  • Metabolism, Inborn Errors / physiopathology
  • Mitochondrial Diseases / diagnosis
  • Mitochondrial Diseases / drug therapy*
  • Mitochondrial Diseases / enzymology
  • Mitochondrial Diseases / genetics
  • Mitochondrial Diseases / physiopathology
  • Muscular Diseases / diagnosis
  • Muscular Diseases / drug therapy*
  • Muscular Diseases / enzymology
  • Muscular Diseases / genetics
  • Muscular Diseases / physiopathology
  • Oxidation-Reduction
  • Treatment Outcome

Substances

  • Fatty Acids
  • Acyl-CoA Dehydrogenase, Long-Chain
  • Carnitine O-Palmitoyltransferase
  • Bezafibrate

Supplementary concepts

  • Carnitine palmitoyl transferase 2 deficiency
  • VLCAD deficiency